London Cartilage Clinic
Explore expert articles on cartilage care, regenerative treatments, and practical recovery advice from our specialist team.
ChondroFiller is a non-surgical, ultrasound-guided outpatient injection used to support joint preservation in osteoarthritis and joint wear. It is a CE-marked, cell-free type I collagen scaffold with a reassuring safety record in published studies. It is not a cure and does not reverse arthritis; benefits vary and individual assessment is essential.
Professor Paul Lee's Regeneration-First approach to joint care centres on preserving your own cartilage before considering replacement surgery. It draws on two distinct pathways: the ChondroFiller injection, a non-surgical ultrasound-guided outpatient procedure, and the Liquid Cartilage surgical protocol, a keyhole technique combining a collagen scaffold with biological adjuncts. This article explains the philosophy, the diagnostics, and how the two treatments differ.
Explore the latest advancements in ankle cartilage repair, from breakthroughs in stem cell therapies and biomaterial scaffolds to gene therapy innovations. This article highlights translational research that bridges laboratory discoveries with clinical treatments like autologous chondrocyte implantation (ACI), improving patient outcomes. Despite challenges in consistent results and cost, ongoing clinical trials and improved imaging techniques promise a future of enhanced healing and joint function. Collaboration between researchers and clinicians is key to delivering effective, personalized therapies and preventing osteoarthritis after cartilage injuries.
ChondroFiller injection, the Liquid Cartilage surgical protocol, and standalone stem cell therapy are three distinct modern options for cartilage wear. Choosing between them depends on the joint, the size and location of the defect, and whether a non-surgical or keyhole surgical approach is appropriate. This article explains how they differ and what assessment involves.
Knee osteoarthritis affects millions, with hyaluronic acid injections offering temporary relief. Arthrosamid, a novel polyacrylamide hydrogel, provides longer-lasting cushioning and pain reduction by forming a stable scaffold in the joint, lasting up to two years. Unlike hyaluronic acid, Arthrosamid causes fewer inflammatory reactions and fewer repeat injections, improving patient comfort and mobility. Led by Professor Paul Lee at the London Cartilage Clinic, this innovative treatment offers hope for sustained symptom management, enhancing quality of life for those with chronic knee osteoarthritis. Consult healthcare professionals to explore the best options for individual needs.
Recent research reveals surprising parallels between healing processes of skull fractures and knee cartilage injuries. Both trigger inflammation and cellular responses vital for repair, though cartilage heals slower due to lack of blood supply. Insights from bone healing, such as balancing inflammation, growth factors, and controlled movement, are now informing improved cartilage treatments. Advances in biomaterials and rehabilitation strategies inspired by neurology and orthopaedics offer promising therapies to accelerate cartilage repair and prevent arthritis. Ongoing collaboration between medical fields aims to develop personalized, innovative solutions enhancing joint health and recovery.
